Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Challenges of personalised oncology

Prof Pier Guiseppe Pelicci - European Institute of Oncology, Milan, Italy

Challenges of personalised oncology ( Prof Pier Guiseppe Pelicci - European Institute of Oncology, Milan, Italy )

Implementing precision medicine in cancer care

Prof Christophe Le Tourneau - Institut Curie, Paris, France

Implementing precision medicine in cancer care ( Prof Christophe Le Tourneau - Institut Curie, Paris, France )

Clinical validity of NGS and innovation in clinical diagnosis

Dr Jeffrey Ross - Albany Medical College, Albany, USA

Clinical validity of NGS and innovation in clinical diagnosis ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )

Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial...

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )

Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma

Dr Jeffrey Graham - Tom Baker Cancer Centre, Calgary, Canada

Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma ( Dr Jeffrey Graham - Tom Baker Cancer Centre, Calgary, Canada )

Genetic mutations: New therapeutic avenues in metastatic prostate cancer

Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Genetic mutations: New therapeutic avenues in metastatic prostate cancer ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

6-factor prognostic model for patients with advanced urothelial carcinoma

Dr Gregory Pond - McMaster University, Hamilton, Ontario

6-factor prognostic model for patients with advanced urothelial carcinoma ( Dr Gregory Pond - McMaster University, Hamilton, Ontario )

Comment: Urothelial cancer research from ASCO GU 2018

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Comment: Urothelial cancer research from ASCO GU 2018 ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and...

Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis ( Dr Lisa Pickering - The Royal Marsden NHS Foundation Trust, London, UK )

Genomic profiling of muscle invasive bladder cancer to predict response to...

Dr David Miyamoto - Massachusetts General Hospital, Boston, USA

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy ( Dr David Miyamoto - Massachusetts General Hospital, Boston, USA )

Tumour fraction in circulating free DNA as a biomarker of disease dynamics in...

Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA

$Tumour fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer ( Dr Atish Choudhury - Dana-Farber Cancer Institute, Boston, USA )$

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or...

Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification ( Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium )

More from ecancer